Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Krystal Biotech Inc(KRYS)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for KRYS
10/08/2026: KRYS (3-star) is currently NOT-A-BUY. Pass it for now.
Krystal Biotech is a commercial-stage biotechnology company known for its unique STAR-D gene therapy platform and the first FDA-approved redosable topical gene therapy, VYJUVEK. Its main strengths lie in its specialized platform technology and its successful transition from an R&D firm to a commercial provider. The company's primary growth opportunity centers on expanding its pipeline into respiratory and ophthalmic conditions while increasing adoption of its current product. Key risks include heavy dependence on a single commercial asset, high operational costs, and intense competition in the rare disease space. The stock may suit growth-oriented investors who can tolerate the volatility typical of clinical-stage biotech companies.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company offers exposure to high-growth potential in the emerging gene therapy market. |
| Momentum investor | Strong fit while signal remains positive | Share price performance often tracks clinical trial results and regulatory milestones. |
| Value investor | Weak fit | The company is in a high-growth phase and valuation is based on future potential rather than current earnings multiples. |
| Dividend investor | Weak fit | Krystal Biotech does not pay dividends as it prioritizes capital for reinvestment. |
| Low-risk investor | Weak fit | Biotechnology stocks are inherently volatile due to clinical and regulatory uncertainties. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is susceptible to large price swings based on clinical data releases. |
| Valuation risk | Medium / high | Valuations in the biotech sector often rely on optimistic long-term pipeline assumptions. |
| Competition risk (Gene Therapy) | Medium | Large pharma companies are investing heavily in competing genetic treatment modalities. |
| Business quality | Medium | The business has established commercial credibility but remains dependent on a narrow product base. |
| Dividend income | Low / none | The company does not provide income through dividends. |
| Execution risk | Medium / high | Success depends on the ongoing ability to manufacture and distribute complex gene therapies. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 12.58% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/08/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 9.61B USD | Price to earnings Ratio 40.67 | 1Y Target Price 392.11 |
Price to earnings Ratio 40.67 | 1Y Target Price 392.11 | ||
Volume (30-day avg) 279.7K shares | Beta 0.5 | 52 Weeks Range 179.19 - 382.54 | Updated Date 10/08/2026 |
52 Weeks Range 179.19 - 382.54 | Updated Date 10/08/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 7.98 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Commercial Gene Therapy | Revenue generated from the sale of VYJUVEK for DEB patients. | The company makes money by selling its FDA-approved gene therapy directly to hospitals and specialized pharmacies. |
| Geography | Primarily North American revenue with potential for global expansion. | Current revenue is concentrated in the US market, with future growth dependent on international regulatory approvals. |
Valuation
Trailing PE 40.67 | Forward PE 46.95 | Enterprise Value 9.28B | Price to Sales(TTM) 21.81 |
Enterprise Value 9.28B | Price to Sales(TTM) 21.81 | ||
Enterprise Value to Revenue 21.06 | Enterprise Value to EBITDA 45.39 | Shares Outstanding 29.60M | Shares Floating 23.62M |
Shares Outstanding 29.60M | Shares Floating 23.62M | ||
Percent Insiders 10.66 | Percent Institutions 102.44 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Krystal Biotech Inc
Exchange NASDAQ | Headquarters Pittsburgh, PA, United States | ||
IPO Launch date 2017-09-20 | Founder, Chairman, President & CEO Mr. Krish S. Krishnan M.B.A., M.S. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 295 | Website https://www.krystalbio.com |
Full time employees 295 | Website https://www.krystalbio.com | ||
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.